Iloprost Pharmamentum (Iloprost Trometamol)

Iloprost Trometamol is a prostacyclin (IP) receptor agonist. By binding to these receptors on vascular smooth‑muscle cells, it raises cyclic AMP levels, causing vasodilation and reducing platelet aggregation, which together lower pulmonary arterial pressure and improve tissue perfusion.

The dosing regimen for Iloprost Pharmamentum is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and treatment duration based on the patient’s clinical condition, response, and tolerance.

Safety data for Iloprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Iloprost is a prostacyclin analog, offering rapid vasodilatory effects via IP‑receptor activation. Compared with endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, Iloprost provides a distinct mechanism and is often used when patients need additional or alternative vasodilation, especially in advanced disease.

Iloprost Pharmamentum must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. Use aseptic techniques during preparation and keep the product in its original packaging until administration.

Iloprost Pharmamentum is given by intravenous infusion under the supervision of qualified healthcare professionals. The infusion rate and duration are set by the prescriber and may be adjusted based on the patient’s hemodynamic response and tolerability.

Serious risks include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, and cardiac arrhythmias. Patients should be monitored closely for these events, especially during initiation and dose adjustments.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with active uncontrolled bleeding, severe hypotension, or in whom potent vasodilators are contraindicated. Clinical judgment is required for each individual case.